Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+

Autor:	Govindan, R, Dols, MC, Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Vidal, O, Stewart, D, Ardizoni, A, Weaver, J, Wolfsteiner, M, Reck, M, Talbot, D, Morgensztern, D, Ong, TJ
Jazyk:	angličtina
Rok vydání:	2020
DOI:	10.1016/j.jtho.2017.09.534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______1064::e408eae99a38096662166a6723debc1f https://doi.org/10.1016/j.jtho.2017.09.534 Zobrazit plný text záznamu